CAMBRIDGE, Mass., Dec. 18,
2023 /PRNewswire/ -- Blueprint Medicines Corporation
(Nasdaq: BPMC) today announced that Kate
Haviland, Chief Executive Officer, will present a corporate
overview and 2024 outlook at the 42nd Annual J.P. Morgan
Healthcare Conference on Monday, January 8,
2024, at 10:30 a.m. PT
(1:30 p.m. ET).
A live webcast of the presentation will be available by visiting
the Investors & Media section of Blueprint Medicines' website
at http://ir.blueprintmedicines.com. A replay of the webcast will
be archived on Blueprint Medicines' website for 30 days following
the presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that
invents life-changing therapies for people with cancer and blood
disorders. Applying an approach that is both precise and agile, we
create medicines that selectively target genetic drivers, with the
goal of staying one step ahead across stages of disease. Since
2011, we have leveraged our research platform, including expertise
in molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate science into a broad pipeline of
precision therapies. Today, we have brought our approved medicines
to patients in the United States
and Europe, and we are globally
advancing multiple programs for mast cell disorders, including
systemic mastocytosis and chronic urticaria, breast cancer and
other cancers vulnerable to CDK2 inhibition, as well as EGFR-mutant
lung cancer. For more information, visit www.BlueprintMedicines.com
and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-42nd-annual-jp-morgan-healthcare-conference-302017173.html
SOURCE Blueprint Medicines Corporation